One step closer to improving ER+ breast cancer patients’ response to therapy
A new study from researchers at Baylor College of Medicine brings hope for a more personalized approach to treat estrogen receptor-positive (ER+) breast cancer, the most common type of this cancer. The team identified a biomarker in preclinical ER+ breast cancer models that indicates that the tumor is more likely to respond to treatment with CDK4/6 inhibitors. The findings support further clinical studies to determine whether this marker may help identify patients who could benefit from CDK4/6 inhibitors. The study appeared in Science Translational Medicine.
ER+ breast ...